CAN-2409
BrTK02
Phase 2 mab completed
Quick answer
CAN-2409 for Malignant Glioma is a Phase 2 program (mab) at Candel Therapeutics with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Candel Therapeutics
- Indication
- Malignant Glioma
- Phase
- Phase 2
- Modality
- mab
- Status
- completed